Arrow Generiques Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: Arrow Generiques Pharmaceutical Import Records from India — 7 Products, $6.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Arrow Generiques — Pharmaceutical Importer Profile (2026) | 7 Products, $6.0M Trade | TransData Nexus

Arrow Generiques

Pharmaceutical Importer · France · Cardiovascular Focus · $6.0M Total Trade · DGFT Verified

Arrow Generiques is a pharmaceutical importer based in France with a total trade value of $6.0M across 7 products in 5 therapeutic categories. Based on 371 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Arrow Generiques sources from 2 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 99.9% of imports.

Arrow Generiques — Import Portfolio & Supplier Network

Arrow Generiques import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Arrow Generiques?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$66.8M	4,257	99.9%
Lupin Limited	$55.4K	2	0.1%

Arrow Generiques sources from 2 verified Indian suppliers across 2,279 distinct formulations.

What Formulations Does Arrow Generiques Import?

Formulation	Value	Ships
Macrogol 4000 powder for oral solution	$1.6M	72
Amoxicillin capsules 500MG	$663.9K	14
Cetirizine hydrochoride tablets 10MG	$514.4K	15
Metformin tablets 850MG (metformine	$408.2K	17
Metformin 1000 MG tablets(metformine	$402.4K	16
Clopidogrel tablets 75MG (clopidogrel	$368.1K	8
Macrogol 4000 powder for oral solution in sachet 10g 20's(macrogol 4000 arrow 10g, poudre pour solution buvable	$350.3K	10
Atorvastatin 80 MG tablets	$310.1K	11
Metformin tablets 500MG(metformine	$301.0K	12
Lercanidipine tablets 20MG	$300.6K	8
Paracetamol powder for oral solution	$298.2K	17
Atorvastatin 40 MG tablets(atorvastatine	$297.7K	15
Valaciclovir tablets 500	$289.8K	7
Lercanidipine tablets	$281.3K	13
Hydrochloro thiazide tablets 25MG	$270.9K	8

Arrow Generiques imports 2,279 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Irbesartan	Cardiovascular	$2.0M	84	1.9%	10
2	Furosemide	Diuretics	$1.3M	56	1.8%	14
3	Propranolol	Cardiovascular	$681.4K	17	0.6%	12
4	Loratadine	Antihistamines & Allergy	$677.4K	44	0.4%	17
5	Melatonin	Nutritional Supplements	$568.3K	46	3.4%	7
6	Repaglinide	Advanced Diabetes Medications	$497.5K	94	4.9%	9
7	Acarbose	Advanced Diabetes Medications	$367.7K	30	2.9%	6

Arrow Generiques imports 7 pharmaceutical products across 5 categories into France totaling $6.0M.

Arrow Generiques — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Arrow Génériques is a French pharmaceutical company specializing in the importation and distribution of generic medications. Established in 1956, the company is headquartered at 26 Avenue Tony Garnier, 69007 Lyon, France. (meddispar.fr) Arrow Génériques offers a diverse portfolio that includes reimbursed and non-reimbursed generics, ethical drugs, over-the-counter (OTC) products, medical devices, and dermo-cosmetics. (pharmacieanglofrancaise.fr)

In 2014, Arrow Génériques was acquired by Aurobindo Pharma Limited, an Indian multinational pharmaceutical company. This acquisition has enabled Arrow Génériques to leverage Aurobindo's extensive manufacturing capabilities and global supply chain, enhancing its position in the French pharmaceutical market. (lemonde.fr) As a key player in France's pharmaceutical distribution network, Arrow Génériques collaborates with various stakeholders, including wholesalers, parallel importers, hospital suppliers, and logistics intermediaries, to ensure the efficient delivery of pharmaceutical products across the country.

2Distribution Network

Arrow Génériques operates a comprehensive distribution network within France, with its primary facility located in Lyon. The company utilizes advanced logistics capabilities to manage the importation and distribution of pharmaceutical products, ensuring timely and efficient delivery to pharmacies, hospitals, and other healthcare providers nationwide. While specific details about additional warehouse locations and geographic coverage beyond France are not publicly disclosed, Arrow Génériques' affiliation with Aurobindo Pharma Limited suggests access to a broader international distribution network, potentially facilitating exports to other European markets.

3Industry Role

Arrow Génériques functions as a pharmaceutical importer and distributor within France's supply chain. By sourcing generic medications from international manufacturers, including its parent company Aurobindo Pharma Limited, Arrow Génériques plays a crucial role in providing cost-effective alternatives to branded drugs. This position supports the French healthcare system by enhancing access to essential medications and promoting competition within the pharmaceutical market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Arrow Generiques

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Arrow Génériques demonstrates a high level of sourcing concentration, with 99.9% of its pharmaceutical imports from India supplied by Aurobindo Pharma Limited. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and potentially benefit from favorable pricing and consistent product quality. However, such concentration also exposes the company to risks associated with supply chain disruptions, regulatory changes, or operational challenges within Aurobindo Pharma Limited. The stability of this relationship is crucial for Arrow Génériques' operations, and any significant issues with the supplier could impact the company's ability to meet market demand.

2Supply Chain Resilience

The resilience of Arrow Génériques' Indian supply chain is closely tied to its exclusive partnership with Aurobindo Pharma Limited. While this relationship offers advantages in terms of supply chain efficiency and product consistency, it also presents challenges. The lack of backup suppliers means that any disruptions at Aurobindo's facilities—such as production delays, quality control issues, or regulatory non-compliance—could directly affect Arrow Génériques' ability to supply products to the French market. Additionally, the reliance on a single supplier may limit the company's flexibility in responding to changes in market demand or regulatory requirements.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). The ANSM is responsible for ensuring the safety, efficacy, and quality of health products, including pharmaceuticals. Key legislation governing pharmaceutical imports includes the Public Health Code (Code de la santé publique), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. For Indian generics to be marketed in France, they must obtain a marketing authorization from the ANSM, demonstrating compliance with French and European Union (EU) standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in France stipulate that all imported medicines must have a valid marketing authorization issued by the ANSM. Additionally, the manufacturing facilities of the exporting company must adhere to Good Manufacturing Practice (GMP) standards recognized by the EU, WHO, or PIC/S. This ensures that imported products meet the quality standards expected in the French market. Wholesale distribution authorization is also required for entities involved in the distribution of pharmaceutical products within France, ensuring compliance with national regulations and standards.

Arrow Generiques — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Arrow Génériques' focus on importing generic medications in therapeutic areas such as cardiovascular, diuretics, and advanced diabetes reflects a strategic alignment with prevalent health concerns in France. The high import values in these categories indicate strong market demand and the company's commitment to providing accessible treatment options for chronic conditions. By concentrating on these therapeutic areas, Arrow Génériques addresses significant public health needs while positioning itself as a key supplier in these segments.

2Sourcing Profile

Arrow Génériques' sourcing strategy emphasizes the importation of generic drugs from India, leveraging the country's robust pharmaceutical manufacturing sector. The company's preference for finished pharmaceutical formulations, rather than raw active pharmaceutical ingredients (APIs), suggests a focus on ready-to-market products that meet French regulatory standards. This approach allows Arrow Génériques to efficiently expand its product portfolio and respond to market demands with agility.

3Market Positioning

With a product mix that includes generics, OTC products, and medical devices, Arrow Génériques serves a broad segment of the French pharmaceutical market. The company's offerings cater to both retail pharmacies and hospital settings, providing essential medications and health products to a wide range of patients. This diverse portfolio enables Arrow Génériques to maintain a competitive position across various distribution channels within the French healthcare system.

Seller's Guide — How to Become a Supplier to Arrow Generiques

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the French market by partnering with Arrow Génériques. The company's established distribution network and focus on high-demand therapeutic areas create avenues for additional products that meet French regulatory standards. Identifying gaps in Arrow Génériques' current sourcing, such as specific formulations or dosage forms not currently imported, could present opportunities for new suppliers to fulfill unmet market needs.

2Requirements & Qualifications

Indian exporters seeking to supply Arrow Génériques and the French market must ensure that their products have valid marketing authorizations from the ANSM. Manufacturing facilities must comply with GMP standards recognized by the EU, WHO, or PIC/S. Additionally, products must meet French labeling requirements, including French language labeling and serialization mandates. Adhering to these standards is essential for gaining access to the French pharmaceutical market.

3How to Approach

Frequently Asked Questions — Arrow Generiques

What products does Arrow Generiques import from India?

Arrow Generiques imports 7 pharmaceutical products across 5 categories. Top imports: Irbesartan ($2.0M), Furosemide ($1.3M), Propranolol ($681.4K), Loratadine ($677.4K), Melatonin ($568.3K).

Who supplies pharmaceuticals to Arrow Generiques from India?

Arrow Generiques sources from 2 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (99.9% of imports, $66.8M).

What is Arrow Generiques's total pharmaceutical import value?

Arrow Generiques's total pharmaceutical import value from India is $6.0M, based on 371 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Arrow Generiques focus on?

Arrow Generiques imports across 5 categories. The largest: Cardiovascular (44.2%), Diuretics (20.8%), Advanced Diabetes Medications (14.3%).

Get Full Arrow Generiques Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.